Search research articles
Contact Us
Filters
Showing results (11-20 of 88) with videos related to
Page
of 9
Sort By:
Expert Review of Clinical Pharmacology
|
August 28, 2019
Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia
Christine M McMahon, Alexander E Perl
Leukemia & Lymphoma
|
September 21, 2018
Management of primary refractory acute myeloid leukemia in the era of targeted therapies
Christine M McMahon, Alexander E Perl
Cancer Journal (Sudbury, Mass.)
|
January 24, 2022
Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia: The Case for Total Therapy
Alexander E Perl, Keith W Pratz
Blood Advances
|
April 5, 2019
Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia
Pamela J Sung, Mayumi Sugita, Holly Koblish, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2011
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy
Alexander E Perl, Margaret T Kasner, Doris Shank, et al.
Cancer Medicine
|
December 19, 2020
The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia
Jessica K Altman, Alexander E Perl, Jason E Hill, et al.
Blood Advances
|
February 7, 2022
Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
Catherine C Smith, Mark J Levis, Alexander E Perl, et al.
Frontiers in Oncology
|
May 28, 2021
Radiation Therapy for Chemotherapy Refractory Gingival Myeloid Sarcoma
Daniel Y Lee, Jonathan Baron, Christopher M Wright, et al.
Blood Advances
|
February 11, 2020
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations
Theodore C Tarver, Jason E Hill, Leena Rahmat, et al.
The Lancet. Haematology
|
October 23, 2021
Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
Hagop Kantarjian, Nicholas J Short, Courtney DiNardo, et al.
Page
of 9
Search research articles
Search
Showing results (11-20 of 88) with videos related to
Sort By:
Page
of 9
Expert Review of Clinical Pharmacology
|
August 28, 2019
Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia
Christine M McMahon, Alexander E Perl
Leukemia & Lymphoma
|
September 21, 2018
Management of primary refractory acute myeloid leukemia in the era of targeted therapies
Christine M McMahon, Alexander E Perl
Cancer Journal (Sudbury, Mass.)
|
January 24, 2022
Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia: The Case for Total Therapy
Alexander E Perl, Keith W Pratz
Blood Advances
|
April 5, 2019
Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia
Pamela J Sung, Mayumi Sugita, Holly Koblish, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2011
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy
Alexander E Perl, Margaret T Kasner, Doris Shank, et al.
Cancer Medicine
|
December 19, 2020
The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia
Jessica K Altman, Alexander E Perl, Jason E Hill, et al.
Blood Advances
|
February 7, 2022
Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
Catherine C Smith, Mark J Levis, Alexander E Perl, et al.
Frontiers in Oncology
|
May 28, 2021
Radiation Therapy for Chemotherapy Refractory Gingival Myeloid Sarcoma
Daniel Y Lee, Jonathan Baron, Christopher M Wright, et al.
Blood Advances
|
February 11, 2020
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations
Theodore C Tarver, Jason E Hill, Leena Rahmat, et al.
The Lancet. Haematology
|
October 23, 2021
Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
Hagop Kantarjian, Nicholas J Short, Courtney DiNardo, et al.
Page
of 9